Glenmark receives ANDA approval from U.S. FDA for Hydralazine Hydrochloride Tablets
By TMI | June 1, 2009
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release
dated June 01, 2009 titled “Glenmark receives ANDA approval from U.S.
FDA for Hydralazine Hydrochloride Tablets”.
Topics: Buzzing Stocks |
« Religare and Swiss Re join hands to enter India health insurance space | Home | Veer Energy Board recommends Final Dividend & Bonus Shares »